

State of the Life Sciences Market

Outcome Capital



Reach the Right Outcome


LIFE SCIENCES INDICES UNDERPERFORM VS. S&P500



2024: State of the Life Sciences Market


Key Insights

- Key macroeconomic factors including lowering interest rates and election cycle impacting overall life sciences market performance in similar fashion to broader market
- Biotech segment viewed by investors as more speculative, valuing clinical data/commercial potential as opposed to traditional financial metrics; XBI demonstrates more volatility with steep early Q2 downturn but Q3 tracks S&P performance
- Earnings-driven MedTech index mimicked S&P 500, but due to poor earnings across industry demonstrated weaker returns



M&A DEALMAKING REBOUNDS IN 2024 VS. 2023 2024: State of the Life Sciences Market






Accelerated Life Science Deal Making Activity in 2024 After Sluggish Performance in 2023

^Based on transactions with disclosed values; #Includes transactions with undisclosed values

INCREASED CAPITAL DEPLOYMENT WITH UPSIZED VC DEALS 2024: State of the Life Sciences Market





Significant Investment In Clinical Stage

^Based on transactions with disclosed values; #Includes transactions with undisclosed values

NOTABLE DEVELOPMENTS DEFINING BIOPHARMA INDUSTRY





2024: State of the Life Sciences Market

Biopharma Tailwinds Welcome to the "GLP-1" age

- Many Pharma/Biotech Cos are focused on new iterations of weight loss drugs with reduced side effects and lower costs.
- In June, at the American Diabetes Association conference, 27 new GLP-1 drugs were reported in development, some of which target a different hormone.
- Early data implicating new potential indications for GLP-1 drugs in Alzheimer's Disease. Teva launched the first GLP-1 generic, Victoza, in the US.

Advances in Alzheimer's

- Lilly received FDA approval for Kisunla, on the heels of Leqembi (by Biogen/Eisai) in early 2023. With upwards of 7M+ Americans with AD, these two drugs are targeting beta-amyloid, the toxic protein that accumulates in the brains of those with Alzheimer's disease
- Abbvie's recent acquisition of Aliada Therapeutics& Takeda's Licensing Agreements with AC Immune demonstrates continued strategic interest in building Alzheimers therapeutic pipeline

Biopharma Headwinds

Inflation Reduction Act (IRA)

- US Dept Health & Human Services announced the first round of Medicare price reductions under the IRA.
- Pricing reductions averaged 60% (38-79%).
- Worst hit drugs were Merck's Januvia (cut 79%) and Novo Nordisk's Fiasp (cut 76%).


The BIOSECURE Act

 If passed by the Senate and signed into law, this legislation would prohibit federal agencies from procuring, purchasing, or obtaining biotechnology equipment or services from a biotechnology company that is controlled or operated on behalf of a foreign adversary, most notably Chinese CDMOs, CROs and drug developers.

UPTICK IN 2024 IPOS WITH MORE FOCUSED COMPANY PROFILE



2024: State of the Life Sciences Market



- ✓ 2024 Biopharma IPOs through Q3 have surpassed total from 2023 although the deal total remains far below the high of 2021 (45).
- ✓ Strong end of Q3 after summer Iull; >\$900M raised since 9/1/2024
- ✓ IPO focused on later-stage, clinical assets in high-growth markets across oncology, neurology & autoimmune

deress erreelegy	, noorology a abroinmitterio				
	2024 IPO Recipe				
Late-stage clinical asset	Multiple near- term catalysts	Strong investor syndicates	Biosciences \$188M	48%	IPO supports MBX's precision peptide therapy pipeline, including two assets in clinical trials

Company	Proceeds	∆ Value (%)	Financing Overview			
C ONCOLOGY	\$380M	96%	Proceeds to support late-stage trial of bladder cancer therapy			
BICARA therapeutics	\$362M	40%	Proceeds will advance Phase II/III development of a bifunctional EGFR/TGF-β antibody for solid tumors			
Zenas BioPharma	\$260M	10%	IPO to advance Phase II and Phase III trials of obexelimab for treating inflammatory disorders			
	\$198M	22%	Proceeds to support Phase II trial for lead weight loss asset, azelaprag in combination with Eli Lilly's tirzepatide			
Biosciences	\$188M	48%	IPO supports MBX's precision peptide therapy pipeline, including two assets in clinical trials			


Recent 2024 BioPharma IPOs

Recent Momentum In The IPO Activity Signals Better Days Ahead For 2024 Public Markets

ONCOLOGY & IMMUNOLOGY LEADING BIOPHARMA M&A



2024: State of the Life Sciences Market



Assets With Clinical Proof of Concepts Or Commercial Traction Driving Deal Making

ABased on transactions with disclosed values; #Includes transactions with undisclosed values

MID-CAP ACQUISITIONS TAKE CENTER STAGE IN 2024



2024: State of the Life Sciences Market

2023 Top 5 M&A					
TARGET	BUYER	DEAL SIZE			
Seagen	P fizer	\$43.0B			
	t ^{illi} Bristol Myers Squibb ⁻	\$14.0B			
		\$10.8B			
immun•gen.	abb∨ie	\$10.1B			
Cerevel	abb∨ie	\$8.7B			



- After 2023 was marked by multiple \$10B+ M&A deals, headlined by Pfizer's acquisition of Seagene, biopharma M&A in 2024 has been categorized with more mid-size deals
- With upcoming patent cliffs and pricing uncertainty due to the IRA, large strategics investing in clinical-stage products in early/mid-stage development to enhance pipeline

Significant M&A Activity For Deals Between \$500-\$5B in 2024

2024 M&A Activity By Size



BIOPHARMA SEGMENT TRENDS: RADIOPHARMACEUTICALS



2024: State of the Life Sciences Market

Radiopharmaceuticals Segment Insights



First Generation Radiopharmaceuticals Faced Challenges

- Production & supply hurdles limited availability to meet strong demand
- Short half life limited usage availability & drove the need for efficient logistics at a higher cost




Second Generation Found Commercial Success

- Improvements in efficacy over existing standards of care & greater inclusion of radiation oncologists in clinical practice
- Positive clinical success in treatment of certain cancers with improved stability & safety

Future of Radiopharmaceuticals

- Effective, safer & easier use molecules spurred renewal in field & consummated a flurry of licensing, M&A & VC activity
- Future development will be focused on effective radiopharmaceuticals for broader range of diseases

Highlighted Biotech/Pharma Investment



Surge In Large Biopharma Interest In Radiopharmaceuticals Continues Into 2024

BIOPHARMA TRANSACTION TRENDS: GLP-1 INVESTMENTS



2024: State of the Life Sciences Market

Obesity Segment Insights

Continued Wave of Obesity & Weight Loss Drug Investments

With record revenues driven by Novo & Lilly's incretin drugs, VCs are investing early & heavily to capitalize on a rapidly developing market

- Multiple early-stage financings demonstrates VCs continued appetite to fund companies developing obesity & weight loss therapeutics
- With a projected market worth more than \$130B in 2030, investors are looking to pursue the "second" generation of obesity medicines to supplant Mounjaro & Wegovy
- Despite promising initial data to incite VC investments, early-stage metabolic companies will be faced with the challenges of competing against Amgen, Roche, Boehringer Ingelheim, and AstraZeneca's promising candidates currently in clinical trials

Additional Representative Transactions



Highlighted Biotech/Pharma Investment: Q2 | 2024



Target Description: Incorporated in May 2024, Kailera is a clinical-stage biotechnology company developing incretin treatments for diabetes, obesity, & weight loss

Transaction Insights

- Leading investor syndicate seeking to benefit from significant strategic interest in obesity drugs
- Kailera acquired phase 3 ready GLP/GIP dual product with hope of developing best-in-class molecule
- Investors leverage data collected in China clinical studies to de-risk investment opportunity

Metabolic Diseases Draw Major Investor Interest in 2024 As Strategic Transaction Activity Is At A High

BIOPHARMA TRANSACTION TRENDS: AI IN BIOPHARMA



2024: State of the Life Sciences Market

Al In Biopharma Segment Insights

2024 Nobel Peace Prize Award Recognizes Value Computational Tools Have On Transforming Biology Processes, Improving Diagnostic Capabilities & Revolutionizing Drug Discovery:

- Accelerate drug discovery by identifying potential drug candidates & predicting protein structures & molecular interactions; currently 67 Alplatform derived drugs in phase II or III clinical as of 2023
- Ability to enhance diagnosis rates and disease identification, especially for cancer diagnostics, enabling quicker access to necessary care and treatment
- Increasing efficiency in production, quality control, and logistics in supply chain & manufacturing of biopharma products



Highlighted Biotech/Pharma Investment: Q2 | 2024



Target Description: Developer of an Al drug discovery platform to design novel, safe, and efficacious compounds for clinical testing

Transaction Insights

- Al offers biopharma companies the opportunity to bring drugs to market faster and more efficiently
- Merger between Exscientia and Recursion is first sign of consolidations among Al-biopharma companies
- Previously, AI-based pharmas have relied on monetizing their platform externally


AI-Based Tools For Drug Discovery & Development Continues To Drive Investment & Deals In Biopharma

For more transaction insights, please refer to the Outcome Capital Pulse at https://www.outcomecapital.com/resources/lifesciences-pulse/

DRIVERS AND CATALYSTS SHAPING MEDTECH INDUSTRY




2024: State of the Life Sciences Market



Continued Device Advancement & Expanded Indications Enable Rapid MedTech Growth

MEDTECH M&A AND VC ACTIVITY UP IN 2024

2024: State of the Life Sciences Market



- Medical device strategics significantly more acquisitive in 2024 compared to prior years; deals withing high-growth indications i.e.; cardiovascular, endovascular and neuromodulation
- Investors continue to be active in the space with financings mainly ٠ focused on later-stage companies with clinical proof-of-concept and/or approval

Highlighted MedTech Investment DEAL SIZE **TECHNOLOGY BUYER** DATE Sacral Scientific \$1.3B Jan. 2024

SHOCKWAVE	Intravascular lithotripsy platform	Johnson&Johnson	\$13.9B	May 2024
JENAVALVE	Trilogy Heart Valve System	E Edwards Lifesciences	\$945M	Jul. 2024
SILKROAD>	Transcarotid artery revascularization	Scientific	\$3.4B	Sep. 2024
	Interatrial shunt	Johnson&Johnson	\$1.7B	Oct. 2024
CereVasc	Endovascular CSF Shunt	t Financings BainCapital ULEE SCIENCES Xontogeny	\$70M Series A	May 2024
	Endoscopic procedure for T2D	HATTERAS VENTURE PARTARS	\$88M Series C	June 2024
·₩• HISTOSONICS	Histotripsy therapy platforms	ALPHA WAVE HealthQuest Johnson&Johnson	\$102M Series D	Aug. 2024
MENDAERA	Surgical robotics		\$73M Series B	Sep. 2024

neuromodulation

therapy

TARGET

Axonics

Cardiovascular, Neuromodulation & Robotics Leading Deal Making Trends For 2024

ABased on transactions with disclosed values; #Includes transactions with undisclosed values

2025 INDUSTRY OUTLOOK



2024: State of the Life Sciences Market

Steady Climb in M&A Activity For The Rest of 2024 & Into 2025

- Biopharma strategics continue to depend on M&A for growth & replenish their portfolios
- Continued search for new disruptive opportunities such as GLP-1 therapeutics, Radiopharmaceuticals & AI-based platforms

IPO Candidates & Bankers Approaching Rest Of The Year Cautiously

- Election & geopolitical concerns cause hesitancy around IPO environment for Life Sciences
- As clarity on the political scene & interest rate emerges, there is growing conviction for a stronger IPO market next year

Increased Confidence In The Financial Outlook Over The Next 12 Months

- Overall cash runways are improving, alongside favorable economic conditions & interest rate cuts, leading to potential robust deal activity in late 2024 & 2025
- VC fundraising expected to continue attracting LP investment leading to availability of capital







Headquarters Office:



20 Custom House Street Suite 1200 Boston, MA 02110 +1 (617)431-2278

International Offices:

Via A. Galli, 2 6900 Lugano, Switzerland 1305 South Suzhou Road, 2F Shanghai, China Global Reach

FINTA SIPC